EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Continuing chemotherapy beyond 6 cycles increases the chances of complete cytoreduction surgery in patients with advanced ovarian cancer

Anna Myriam Perrone, Francesco Mezzapesa, Lucia Genovesi, Camelia Alexandra Coada, Elena Masina, Elisabetta Pia Bilancia, Daniela Rubino, Claudio Zamagni, Pierandrea De Iaco

European Journal of Surgical Oncology · 2025

DOI: 10.1016/j.ejso.2025.110288 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Journal of Surgical Oncology, 2025. Verfasst von Anna Myriam Perrone und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy; Division of Oncologic Gynecology, IRCCS Azienda Ospedalie…. Hauptthemen laut MEDLINE: Cytoreduction Surgical Procedures, Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To evaluate the impact of receiving more than 6 cycles of NACT on survival outcomes and chemotherapy-related toxicity in patients with advanced epithelial ovarian cancer (AOEC) ineligible for primary debulking surgery. METHODS: This retrospective, monocentric, observational study analyzed AEOC patients who received at least 6 cycles of NACT followed by IDS. They were grouped by number of NACT cycles (6 vs ≥ 7) and cytoreduction rate (CC0 vs CC ≥ 1), with a non-surgical group for comparison. RESULTS: A total of 335 patients were evaluated over a 20-year period. Pre-surgical variables were similar across groups, except for older age (p < 0.001) and higher Peritoneal Cancer Index (PCI) (p = 0.04) in the non-surgery cohort. Chemotherapy-related toxicities led to delays in subsequent NACT cycles, mainly in the non-surgery group (p = 0.02). After a median follow-up of 67.7 months, patients with CC0 demonstrated the longest median progression-free survival (PFS): 22 months (NACT=6) vs 21 months (NACT≥7). In CC ≥ 1 patients, PFS was 15 months (NACT=6) and 19 months (NACT≥7), while the non-surgery group had 10 months. CC0 was the primary predictor of overall survival (OS). Patients with CC0-NACT=6 had a median OS of 59 months, compared to 40 months for CC0-NACT≥7 group (p = 0.4), while patients with CC≥1, both NACT=6 and NACT≥7 presented a median OS of 27 months. Achieving CC0 after NACT≥7 significantly improved survival compared to NACT=6-CC≥1 (HR = 1.71, p = 0.019 for PFS; HR = 2.1, p = 0.009 for OS). CONCLUSIONS: Extending NACT beyond 6 cycles may benefit selected patients by enhancing cytoreduction rates and survival without increasing toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytoreduction Surgical ProceduresOvarian NeoplasmsCarcinoma, Ovarian EpithelialAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleRetrospective StudiesMiddle AgedAgedSurvival RateAdultProgression-Free SurvivalNeoplasm StagingChemotherapy, AdjuvantDrug Administration ScheduleAged, 80 and over

Stichwörter der Autor:innen

Delayed debulking surgeryNACTOvarian cancerPeritoneal cancer indexResidual diseaseToxicity

Autor:innen und Institutionen

  • Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy; Division of Oncologic Gynecology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy; Division of Oncologic Gynecology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. Electronic address: lucia…
  • Department of Morpho-functional sciences, University of Medicine and Pharmacy "Iuliu Hațieganu", Cluj-Napoca, Romania.
  • Division of Oncologic Gynecology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Förderung

  • Ministero della Salute

Zitieren

APA

Perrone, A. M., Mezzapesa, F., Genovesi, L., Coada, C. A., Masina, E., Bilancia, E. P., Rubino, D., Zamagni, C., & De Iaco, P. (2025). Continuing chemotherapy beyond 6 cycles increases the chances of complete cytoreduction surgery in patients with advanced ovarian cancer. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2025.110288

Vancouver

Perrone AM, Mezzapesa F, Genovesi L, Coada CA, Masina E, Bilancia EP, et al. Continuing chemotherapy beyond 6 cycles increases the chances of complete cytoreduction surgery in patients with advanced ovarian cancer. European Journal of Surgical Oncology. 2025. doi:10.1016/j.ejso.2025.110288

BibTeX
@article{Perrone2025,
  author = {Perrone, Anna Myriam and Mezzapesa, Francesco and Genovesi, Lucia and Coada, Camelia Alexandra and Masina, Elena and Bilancia, Elisabetta Pia and Rubino, Daniela and Zamagni, Claudio and De Iaco, Pierandrea},
  title = {Continuing chemotherapy beyond 6 cycles increases the chances of complete cytoreduction surgery in patients with advanced ovarian cancer},
  journal = {European Journal of Surgical Oncology},
  year = {2025},
  doi = {10.1016/j.ejso.2025.110288}
}
Kostenlos starten →